WT1-targeted immunotherapy of leukaemia

Blood Cells, Molecules, and Diseases

Volumn 33, Issue 3, 2004, Pages 288-290

  Xue, S ^a   Gao, L ^a   Gillmore, R ^a   Bendle, G ^a   Holler, A ^a   Downs, A M ^a   Tsallios, A ^a   Ramirez, F ^a   Ghani, Y ^a   Hart, D ^a   Alcock, S ^a   Tranter, A ^a   Stauss, H J ^b   Morris, E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cancer; CTL; Immunotherapy; Leukaemia; TCR; WT1

Indexed keywords

CANCER VACCINE; CD34 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT WT1 PROTEIN; UNCLASSIFIED DRUG; WT1 VACCINE;

ALLOIMMUNITY; ANTIGEN EXPRESSION; BINDING AFFINITY; CELL SIZE; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DONOR; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HLA SYSTEM; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION;

ANIMALS; EPITOPES, T-LYMPHOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; MICE; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 7444229839     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2004.08.018     Document Type: Conference Paper

References (28)

1. H.J. Kolb, J. Mittermuller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. Heim, and W. Wilmanns Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients Blood 76 1990 2462 2465
2. M.M. Horowitz, R.P. Gale, P.M. Sondel, J.M. Goldman, J. Kersey, H.J. Kolb, A.A. Rimm, O. Ringden, C. Rozman, and B. Speck Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 1990 555 562
3. W.D. Shlomchik, M.S. Couzens, C.B. Tang, J. McNiff, M.E. Robert, J. Liu, M.J. Shlomchik, and S.G. Emerson Prevention of graft versus host disease by inactivation of host antigen-presenting cells Science 285 1999 412 415
4. T. Teshima, R. Ordemann, P. Reddy, S. Gagin, C. Liu, K.R. Cooke, and J.L. Ferrara Acute graft-versus-host disease does not require alloantigen expression on host epithelium Nat. Med. 8 2002 575 581
5. E.C. Guinan, V.A. Boussiotis, D. Neuberg, L.L. Brennan, N. Hirano, L.M. Nadler, and J.G. Gribben Transplantation of anergic histoincompatible bone marrow allografts N. Engl. J. Med. 340 1999 1704 1714
6. P.A. Taylor, C.J. Lees, H. Waldmann, R.J. Noelle, and B.R. Blazar Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions Blood 98 2001 467 474
7. P.A. Taylor, R.J. Noelle, and B.R. Blazar CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade J. Exp. Med. 193 2001 1311 1318
8. H. Groux, A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J.E. de Vries, and M.G. Roncarolo A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Nature 389 1997 737 742
9. M.G. Roncarolo, R. Bacchetta, C. Bordignon, S. Narula, and M.K. Levings Type 1 T regulatory cells Immunol. Rev. 182 2001 68 79
10. P.L. Tazzari, A. Bolognesi, D. De Totero, S. Pileri, R. Conte, J. Wijdenes, P. Herve, M. Soria, F. Stirpe, and M. Gobbi B-B10 (anti-CD25)-saporin immunotoxin-A possible tool in graft-versus-host disease treatment Transplantation 54 1992 351 356
11. M.B. Koh, H.G. Prentice, and M.W. Lowdell Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis Bone Marrow Transplant. 23 1999 1071 1079
12. P. Hoffmann, J. Ermann, M. Edinger, C.G. Fathman, and S. Strober Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation J. Exp. Med. 196 2002 389 399
13. J.L. Cohen, A. Trenado, D. Vasey, D. Klatzmann, and B.L. Salomon CD4(+)CD25(+) Immunoregulatory T cells: new therapeutics for graft-versus-host disease J. Exp. Med. 196 2002 401 406
14. F. Lan, D. Zeng, M. Higuchi, P. Huie, J.P. Higgins, and S. Strober Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells J. Immunol. 167 2001 2087 2096
15. S. Reich-Zeliger, Y. Zhao, R. Krauthgamer, E. Bachar-Lustig, and Y. Reisner Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite Immunity 13 2000 507 515
16. R.E. Clark, I.A. Dodi, S.C. Hill, J.R. Lill, G. Aubert, A.R. Macintyre, J. Rojas, A. Bourdon, P.L. Bonner, L. Wang, S.E. Christmas, P.J. Travers, C.S. Creaser, R.C. Rees, and J.A. Madrigal Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein Blood 98 2001 2887 2893
17. E.H. Warren, P.D. Greenberg, and S.R. Riddell Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution Blood 91 1998 2197 2207
18. A.M. Dickinson, X.N. Wang, L. Sviland, F.A. Vyth-Dreese, G.H. Jackson, T.N. Schumacher, J.B. Haanen, T. Mutis, and E. Goulmy In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens Nat. Med. 8 2002 410 414
19. T. Mutis, and E. Goulmy Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies Semin. Hematol. 39 2002 23 31
20. J.J. Molldrem, P.P. Lee, C. Wang, K. Felio, H.M. Kantarjian, R.E. Champlin, and M.M. Davis Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nat. Med. 6 2000 1018 1023
21. H.J. Stauss Immunotherapy with CTLs restricted by nonself MHC Immunol. Today 20 1999 180 183
22. E. Sadovnikova, L.A. Jopling, K.S. Soo, and H.J. Stauss Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules Eur. J. Immunol. 28 1998 193 200
23. E. Sadovnikova, E.N. Parovichnikova, V.G. Savchenko, T. Zabotina, and H.J. Stauss The CD68 protein as a potential target for leukaemia-reactive CTL Leukemia 16 2002 2019 2026
24. L. Gao, I. Bellantuono, A. Elsasser, S.B. Marley, M.Y. Gordon, J.M. Goldman, and H.J. Stauss Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1 Blood 95 2000 2198 2203
25. I. Bellantuono, L. Gao, S. Parry, S. Marley, F. Dazzi, J. Apperley, J.M. Goldman, and H.J. Stauss Two distinct HLA-A0201-presented epitopes of the Wilms Tumor Antigen 1 can function as targets for leukemia-reactive CTL Blood 100 2002 3835 3837
26. E. Sadovnikova, and H.J. Stauss Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy Proc. Natl. Acad. Sci. U. S. A. 93 1996 13114 13118
27. T. Stanislawski, R.H. Voss, C. Lotz, E. Sadovnikova, R.A. Willemsen, J. Kuball, T. Ruppert, R.L. Bolhuis, C.J. Melief, C. Huber, H.J. Stauss, and M. Theobald Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer Nat. Immunol. 2 2001 962 970
28. H.W. Kessels, M.C. Wolkers, M.D. van den Boom, M.A. van der Valk, and T.N. Schumacher Immunotherapy through TCR gene transfer Nat. Immunol. 2 2001 957 961